KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to -$49.3 million.

  • BeOne Medicines' Cash from Investing Activities rose 63.20% to -$49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$331.4 million, marking a year-over-year increase of 35.94%. This contributed to the annual value of -$548.4 million for FY2024, which is 1013.86% down from last year.
  • Latest data reveals that BeOne Medicines reported Cash from Investing Activities of -$49.3 million as of Q3 2025, which was up 26.02% from -$66.6 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Cash from Investing Activities high stood at $658.7 million for Q2 2022, and its period low was -$209.8 million during Q1 2024.
  • In the last 3 years, BeOne Medicines' Cash from Investing Activities had a median value of -$93.6 million in 2024 and averaged -$66.0 million.
  • In the last 5 years, BeOne Medicines' Cash from Investing Activities surged by 1,512.96% in 2022 and then slumped by 263.76% in 2024.
  • Quarterly analysis of 5 years shows BeOne Medicines' Cash from Investing Activities stood at -$21.2 million in 2021, then spiked by 281.68% to $38.5 million in 2022, then tumbled by 262.40% to -$62.6 million in 2023, then crashed by 49.57% to -$93.6 million in 2024, then spiked by 63.20% to -$49.3 million in 2025.
  • Its Cash from Investing Activities was -$49.3 million in Q3 2025, compared to -$66.6 million in Q2 2025 and -$121.9 million in Q1 2025.